|Awarded On||August 20, 2014|
|Title||Toward the Cure of Myelodysplastic Syndrome: Interfering With Innate Immunity Alterations in Human and Mouse Systems|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Guillermo Garcia-Manero|
The myelosdysplastic syndromes (MDS) are a group of leukemias that affect older individuals. This disease results in progressive anemia, low platelets and increased risk of infections and transformation to acute myelogenous leukemia. At the present time there is no cure for this disease, except for the rare patient that is a candidate for transplantation. Most patients will eventually die from complications of MDS. A decade ago, several new agents with activity in MDS were developed. These included the hypomethylating agents and lenalidomide. Despite this progress, we have not been able to develop any further therapies for these patients in the last five years and their prognosis remains dis...